Skip to content

US · CMND · BIOTECHNOLOGY

Clearmind Medicine Inc. (CMND) intrinsic value and stock valuation

$2.63as of 2026-11-21 · Mkt cap 2.61M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Clearmind Medicine Inc. DCF and intrinsic value

InvestorsCraft values CMND with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CMND’s statements →

Clearmind Medicine Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Vancouver, BC V6H 1A5 clearmindmedicine.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-3.86M
20172025
Free cash flow
-$-4.73M
20172025
Total equity
$1.19M+26.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-5.67M-$-5.74M-$-6.29M-$-9M-$-3.61M
Net income-$-3.86M-$-5.25M-$-8.61M-$-9.93M-$-3.66M
EPSd-$-3.04M-$-6.73M-$-172.2M-$-993M-$-366M
Operating cash flow-$-4.73M-$-6.76M-$-6.3M-$-5.06M-$-2.08M
Capital expenditure$0.00$0.00$0.00-$-10K-$-170K
Free cash flow-$-4.73M-$-6.76M-$-6.3M-$-5.06M-$-2.25M
Total assets$6.08M$10.1M$5.95M$1.12M$4.16M
Total debt$1.78M$70K$0.00$50K$0.00
Net debt-$-2.14M-$-9.08M-$-5.43M-$-120K-$-3.71M
Total equity$1.19M$4.33M$980K-$-1.5M$3.87M
Cash and short-term investments$5.58M$9.55M$5.51M$440K$3.71M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$50K$50K$60K$120K$0.00
Gross profit-$-50K-$-50K-$-60K-$-120K-$0.00
Research and development expenses$2.05M$1.37M$1.53M$4.42M$640K
Selling, general and administrative expenses$3.57M$4.32M$4.71M$4.47M$2.98M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$5.62M$5.69M$6.24M$8.88M$3.61M
Cost and expenses$5.67M$5.74M$6.29M$9M$3.61M
Interest income$130K$270K$60K$0.00$0.00
Interest expense$20K$40K$0.00$20K$0.00
Depreciation and amortization$50K$50K$60K$120K$0.00
Ebitda-$-3.72M-$-4.79M-$-8.53M-$-9.75M-$-3.65M
Operating income-$-5.67M-$-5.74M-$-6.29M-$-9M-$-3.61M
Total other income/expenses, net$1.88M$870K-$-2.3M-$-880K-$-40K
Income before tax-$-3.79M-$-4.88M-$-8.59M-$-9.89M-$-3.66M
Income tax expense$70K$380K$20K$40K$0.00
Net income-$-3.86M-$-5.25M-$-8.61M-$-9.93M-$-3.66M
Weighted average shares outstanding$1.27M$780K$50K$10K$10K
Weighted average diluted shares outstanding$1.27M$780K$50K$10K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$5.58M$9.55M$5.51M$440K$3.71M
Net receivables$320K$250K$240K$130K$130K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.95M$9.87M$5.79M$590K$3.97M
Property, plant and equipment, net$20K$70K$0.00$70K$20K
Goodwill and intangible assets$100K$150K$160K$180K$160K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$140K$230K$160K$530K$190K
Total assets$6.08M$10.1M$5.95M$1.12M$4.16M
Accounts payable$680K$730K$620K$1.9M$280K
Short-term debt$1.78M$50K$0.00$50K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.89M$5.75M$4.97M$2.62M$290K
Long-term debt$0.00$20K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$20K$0.00$0.00$0.00
Capital lease obligations$20K$70K$0.00$50K$0.00
Total liabilities$4.89M$5.77M$4.97M$2.62M$290K
Common stock$26.4M$33.6M$17.1M$9.1M$6.38M
Retained earnings-$-27.88M-$-33.44M-$-18.77M-$-13.77M-$-3.58M
Accumulated other comprehensive income (loss)-$-20K-$-30K-$-20K-$-30K$0.00
Total equity$1.19M$4.33M$980K-$-1.5M$3.87M
Total investments$1.66M$400K$90K$260K$0.00
Total debt$1.78M$70K$0.00$50K$0.00
Net debt-$-2.14M-$-9.08M-$-5.43M-$-120K-$-3.71M
Cash flow statement
20252024202320222021
Net income-$-3.86M-$-7.31M-$-8.62M-$-9.36M-$-2.73M
Depreciation and amortization$50K$70K$60K$110K$0.00
Stock-based compensation$810K$1.39M$510K$1.64M$620K
Change in working capital-$-40K-$-180K-$-970K$1.68M$20K
Accounts receivable$20K$90K-$-150K$30K-$-120K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00-$-620K$0.00$250K
Net cash provided by operating activities-$-4.73M-$-6.76M-$-6.3M-$-5.06M-$-2.08M
Investments in property, plant and equipment$0.00$0.00$0.00-$-10K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-540K-$-330K-$-30K-$-10K-$-180K
Common stock issued$420K$3.05M$11.1M$790K$5.39M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.62M$8.71M$11.7M$690K$5.39M
Net change in cash-$-2.65M$1.6M$5.3M-$-4.4M$3.13M
Cash at end of period$3.92M$9.15M$5.43M$170K$3.37M
Operating cash flow-$-4.73M-$-6.76M-$-6.3M-$-5.06M-$-2.08M
Capital expenditure$0.00$0.00$0.00-$-10K-$-170K
Free cash flow-$-4.73M-$-6.76M-$-6.3M-$-5.06M-$-2.25M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Clearmind Medicine Inc.

        Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

        CEO
        Adi Zuloff-Shani
        Employees
        4
        Beta
        -1.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Clearmind Medicine Inc. (CMND)?

        InvestorsCraft does not currently publish an intrinsic value for CMND. How the IC value is calculated.

        Is CMND undervalued?

        InvestorsCraft does not publish an undervaluation signal for CMND at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.